Screening Options and Recommendations for Colorectal Cancer

ABSTRACT

Screening reduces the burden of disease from colorectal cancer through early detection of cancerous lesions and removal of precancerous polyps. The ideal colorectal cancer screening modality should be cost-effective, increase life-years gained, permit long intervals between tests with high patient compliance and low risk to the patient. Although no single colorectal cancer screening method is perfect, several options exist. Government agencies and medical societies have published screening recommendations with differing guidelines; yet, despite the lack of a consistent standard, it is clear that colorectal cancer screening is cost-effective. In this review, the authors address several options for screening, identify risks and benefits, and present methods to risk stratify patients. A thorough discussion with the patient about potential benefits and harms is critical before initiating any screening regimen.

KEYWORDS

Screening - colorectal cancer - colonoscopy - fecal occult blood test - virtual colonoscopy

REFERENCES

• 1 Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008.  CA Cancer J Clin. 2008;  58(2) 71-96
• 2 Geiger T M, Miedema B W, Geana M V, Thaler K, Rangnekar N J, Cameron G T. Improving rates for screening colonoscopy: Analysis of the health information national trends survey (HINTS I) data.  Surg Endosc. 2008;  22(2) 527-533
• 3 Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update.  Am J Gastroenterol. 2008;  103(6) 1541-1549
• 4 Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.  Gastroenterology. 2005;  129(2) 422-428
• 5 Allison J E, Sakoda L C, Levin T R et al.. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.  J Natl Cancer Inst. 2007;  99 1462-1470
• 6 Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis.  Cell. 1990;  61(5) 759-767
• 7 Ahlquist D A, Skoletsky J E, Boynton K A et al.. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.  Gastroenterology. 2000;  119(5) 1219-1227
• 8 Tagore K S, Lawson M J, Yucaitis J A et al.. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia.  Clin Colorectal Cancer. 2003;  3(1) 47-53
• 9 Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool.  Clin Gastroenterol Hepatol. 2003;  1(5) 377-383
• 10 Imperiale T F, Ransohoff D F, Itzkowitz S H, Turnbull B A, Ross M E. Colorectal Cancer Study Group . Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.  N Engl J Med. 2004;  351(26) 2704-2714
• 11 Syngal S, Stoffel E, Chung D et al.. Detection of stool DNA mutations before and after treatment of colorectal neoplasia.  Cancer. 2006;  106(2) 277-283
• 12 Duffy M J, van Dalen A, Haglund C et al.. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.  Eur J Cancer. 2003;  39(6) 718-727
• 13 Kim H J, Yu M H, Kim H, Byun J, Lee C. Noninvasive molecular biomarkers for the detection of colorectal cancer.  BMB Rep. 2008;  41 685-692
• 14 Winawer S, Stewart E, Zauber A et al.. A comparison of colonoscopy and double contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group.  N Engl J Med. 2000;  342 1766-1772
• 15 Rex D K, Rahmani E Y, Haseman J H, Lemmel G T, Kaster S, Buckley J S. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice.  Gastroenterology. 1997;  112(1) 17-23
• 16 Levin B, Lieberman D A, McFarland B American Cancer Society Colorectal Cancer Advisory Group et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.  Gastroenterology. 2008;  134(5) 1570-1595
• 17 Cotton P B, Durkalski V L, Pineau B C et al.. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia.  JAMA. 2004;  291 1713-1719
• 18 Rockey D C, Paulson E, Niedzwiecki D et al.. Analysis of air contrast barium enema, computed tomographic colonography and colonoscopy: prospective comparison.  Lancet. 2005;  365 305-311
• 19 Pickhardt P J, Choi J R, Hwang I et al.. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults.  N Engl J Med. 2003;  349 2191-2000
• 20 Johnson C D, Harmsen W S, Wilson L A et al.. Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps.  Gastroenterology. 2003;  125(2) 311-319
• 21 Kim D H, Pickhardt P J, Taylor A J et al.. CT colonography versus colonoscopy for the detection of advanced neoplasia.  N Engl J Med. 2007;  357(14) 1403-1412
• 22 Halligan S, Altman D G, Taylor S A et al.. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting.  Radiology. 2005;  237(3) 893-904
• 23 Newcomb P A, Norfleet R G, Storer B E, Surawicz T S, Marcus P M. Screening sigmoidoscopy and colorectal cancer mortality.  J Natl Cancer Inst. 1992;  84(20) 1572-1575
• 24 Gross C P, Andersen M S, Krumholz H M, McAvay G J, Proctor D, Tinetti M E. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer.  JAMA. 2006;  296(23) 2815-2822
• 25 Mandel J S, Church T R, Bond J H et al.. The effect of fecal occult-blood screening on the incidence of colorectal cancer.  N Engl J Med. 2000;  343(22) 1603-1607
• 26 Thiis-Evensen E, Hoff G, Sauar J et al.. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark polyp study I.  Scand J Gastroenterol. 1999;  34 414-420
• 27 Singh H, Turner D, Xue L, Targownik L E, Bernstein C N. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies.  JAMA. 2006;  295(20) 2366-2373
• 28 Winawer S J, Zauber A G, Ho M N The National Polyp Study Work Group et al. Prevention of colorectal cancer by colonoscopic polypectomy.  N Engl J Med. 1993;  329(27) 1977-1981
• 29 Rex D K, Cutler C S, Lemmel G T et al.. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies.  Gastroenterology. 1997;  112(1) 24-28
• 30 Pickhardt P J, Nugent P A, Mysliwiec P A, Choi J R, Schindler W R. Location of adenomas missed by optical colonoscopy.  Ann Intern Med. 2004;  141(5) 352-359
• 31 Barclay R L, Vicari J J, Doughty A S, Johanson J F, Greenlaw R L. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy.  N Engl J Med. 2006;  355(24) 2533-2541
• 32 Johnson C D, Chen M H, Toledano A Y et al.. Accuracy of CT colonography for detection of large adenomas and cancers.  N Engl J Med. 2008;  359(12) 1207-1217
• 33 Cotterill M, Gasparelli R, Kirby E. Colorectal cancer detection in a rural community. Development of a colonoscopy screening program.  Can Fam Physician. 2005;  51 1224-1228
• 34 Kewenter J, Brevinge H. Endoscopic and surgical complications of work-up in screening for colorectal cancer.  Dis Colon Rectum. 1996;  39(6) 676-680
• 35 Ko C, Riffle S, Morris C et al.. Complications after screening and surveillance colonoscopy [Abstract].  Gastroenterology. 2007;  132 A149
• 36 Ko C W, Riffle S, Shapiro J A et al.. Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy.  Gastrointest Endosc. 2007;  65(4) 648-656
• 37 Levin T R, Zhao W, Conell C et al.. Complications of colonoscopy in an integrated health care delivery system.  Ann Intern Med. 2006;  145(12) 880-886
• 38 Nelson D B, McQuaid K R, Bond J H, Lieberman D A, Weiss D G, Johnston T K. Procedural success and complications of large-scale screening colonoscopy.  Gastrointest Endosc. 2002;  55(3) 307-314
• 39 Rathgaber S W, Wick T M. Colonoscopy completion and complication rates in a community gastroenterology practice.  Gastrointest Endosc. 2006;  64(4) 556-562
• 40 Robinson M H, Hardcastle J D, Moss S M et al.. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer.  Gut. 1999;  45(4) 588-592
• 41 Segnan N, Senore C, Andreoni B SCORE Working Group--Italy et al. Baseline findings of the Italian multicenter randomized controlled trial of “once-only sigmoidoscopy”—SCORE.  J Natl Cancer Inst. 2002;  94(23) 1763-1772
• 42 Atkin W S, Hart A, Edwards R et al.. Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening.  Gut. 1998;  42(4) 560-565
• 43 Jain A, Falzarano J, Jain A, Decker R, Okubo G, Fujiwara D. Outcome of 5,000 flexible sigmoidoscopies done by nurse endoscopists for colorectal screening in asymptomatic patients.  Hawaii Med J. 2002;  61(6) 118-120
• 44 Levin T R, Conell C, Shapiro J A, Chazan S G, Nadel M R, Selby J V. Complications of screening flexible sigmoidoscopy.  Gastroenterology. 2002;  123(6) 1786-1792
• 45 Davila R E, Rajan E, Baron T H Standards of Practice Committee, American Society for Gastrointestinal Endoscopy et al. ASGE guideline: colorectal cancer screening and surveillance.  Gastrointest Endosc. 2006;  63(4) 546-557
• 46 Vasen H F, Nagengast F M, Khan P M. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome).  Lancet. 1995;  345 1183-1184
• 47 Konda A, Duffy M.. Surveillance of patients at increased risk of colon cancer: inflammatory bowel disease and other conditions.  Gastroenterol Clin North Am. 2008;  37 191-213
• 48 Thornton J G, Morris A M, Thornton J D, Flowers C R, McCashland T M. Racial variation in colorectal polyp and tumor location.  J Natl Med Assoc. 2007;  99(7) 723-728
• 49 Imperiale T F, Wagner D R, Lin C Y, Larkin G N, Rogge J D, Ransohoff D F. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings.  N Engl J Med. 2000;  343(3) 169-174
• 50 Anderson J C, Alpern Z, Messina C R et al.. Predictors of proximal neoplasia in patients without distal adenomatous pathology.  Am J Gastroenterol. 2004;  99(3) 472-477
• 51 Betes Ibanez M, Munoz-Navas M A, Duque J M et al.. Diagnostic value of distal colonic polyps for prediction of advanced proximal neoplasia in an average-risk population undergoing screening colonoscopy.  Gastrointest Endosc. 2004;  59(6) 634-641
• 52 Zauber A, Lansdrop-Vogelaar I, Knudsen A et al.. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force.  Ann Intern Med. 2008;  149 659-669
• 53 Gross C P, McAvay G J, Krumholz H M, Paltiel A D, Bhasin D, Tinetti M E. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening.  Ann Intern Med. 2006;  145(9) 646-653
• 54 U.S. Preventive Services Task Force . Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement.  Ann Intern Med. 2008;  149(9) 627-637
• 55 Levin B, Lieberman D A, McFarland B American Cancer Society Colorectal Cancer Advisory Group et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.  Gastroenterology. 2008;  134(5) 1570-1595